Ellen Varelas, founder & CEO of LectureLinx, a global provider of innovative compliance technology and services solutions for the biopharmaceutical industry discusses the importance of compliance in the pharma industry.
LectureLinx
Only a few years ago, compliance was the undisputed top priority in the pharmaceutical industry - regardless of cost. Companies operated under the principle that regulatory adherence was paramount, sparing no expense to ensure robust compliance programs.
But today, the landscape has shifted dramatically. Now, organisations are asking a new question: “How can we maintain compliance while aggressively reducing costs?”
And therein lies the collision.
The industry at a crossroads
Last year, the pharmaceutical industry laid off a total of 14,010 jobs in the US - 12,859 more than were lost in 2023. The UK pharmaceutical industry too has experienced notable job reductions. Although the precise total number of layoffs is not publicly available, several major companies implemented significant workforce cuts.
At the end of 2023, Pfizer announced a global drive to save around $3.5 billion by the end of 2024, which included cutting 500 positions at its Sandwich site in Kent. And in a regulatory filing in May 2024, the company outlined plans to reduce costs by an additional $1.5 billion by the end of 2027.
In June this year, ADC Therapeutics announced it was closing its UK R&D site, culling several preclinical programs and trimming its workforce by 30%. The site closure and layoffs are expected to be complete by the end of September this year.
And, more recently, approximately 200 jobs are to be cut in October [2025] at the Barnard Castle facility in County Durham, affecting the team producing the antibiotic, Zinnat.
While layoffs, driven by long-term restructuring efforts, are forcing companies to make tough decisions about resource allocation, compliance requirements are becoming increasingly complex, adding pressure to already lean teams.
Adjusting headcount has fast become a fact of life for the pharmaceutical/ biotech industry - and with compliance needs and requirements becoming tighter (and therefore even more difficult to meet), costing and compliance have become competing priorities in today’s market.
Even companies known for industry-leading compliance programs are now facing the same dilemma. How do they maintain excellence while implementing cost-cutting measures? How do they balance automation and AI-driven efficiency with the need for a strong, personalised healthcare provider (HCP) experience?
Navigating the compliance-cost dilemma
Some organisations with international reach favour a global compliance system. Centralised data, standardised processes, and reduced manual burden are clear benefits. However, implementing such a system is a significant undertaking, requiring both financial and strategic investment.
AI has emerged as a powerful tool in compliance efforts, promising automation, efficiency, and cost reduction. Yet, paradoxically, clients don’t want to pay for a system to do the cost-cutting, nor do they want to pay for system enhancements, even if they drive savings in the long run. They want a system which enables them to be compliant at a lower cost and which requires less people to support the effort. Companies want compliance solutions that are cost-effective, adaptable, and resource-efficient, functioning like an amoeba, shifting shape as needed while still capturing critical compliance data for audits.
Striking the balance between automation and human connection
As with other industries, the pharmaceutical industry is one that’s becoming more and more reliant on technology. But just having the latest, greatest and most up-to-date technology doesn’t guarantee a great HCP experience or ensure your compliance mandate will be met. While automation is undoubtedly key to cost-saving and assured compliance in the long run, it can be a double-edged sword. Technology may be great for automating but not at the cost of human interaction.
HCPs, especially the younger generation of physicians, certainly appreciate automation: they appreciate getting paid quicker and being able to make contracting easier. However, the ‘doing more with less people’ part of automation puts the all-important ‘HCP experience’ at risk - because, ultimately, HCPs don't appreciate losing that higher level connection and relationship.
Therefore, companies must strike a delicate balance: integrating technology while maintaining meaningful connections with HCPs - which means:
- providing innovative, useful technology which your HCPs will want to use – which shows you are keeping up with their needs - and that has the ability to automate as much as possible,
- ensuring automation offers some level of interaction, engagement and connection. The aim is to enhance, not replace, relationships which after the recent layoffs, this will be greatly appreciated by those employees now handling increased workloads, and
- designing communication channels which are easy, intuitive and light touch to use, and can automate as much as possible.
Smart outsourcing: A strategic move
Compliance is everyone's job. It’s a team effort, and it’s all about accountability. In this new era of cost-cutting, it makes little sense to allocate high-value, high-cost internal resources to routine compliance tasks. Outsourcing compliance programs to specialised partners ensures proper contract execution and regulatory reporting without overburdening internal teams. By leveraging external expertise, pharma companies can maintain compliance while optimising operational efficiency.
The power of data analytics in compliance
Data analytics, meanwhile, are fast becoming a cornerstone of modern compliance strategies. Real-time monitoring, early detection of process failures, and dynamic dashboards empower organisations to proactively address compliance risks before they escalate. With fewer employees handling greater workloads, leveraging analytics-driven insights is essential for maintaining compliance without increasing costs.
Future-proofing compliance programs
Regulatory landscapes shift with changes in government policies and corporate leadership. What is acceptable today may not align with tomorrow’s mandates. To remain agile, companies need compliance systems that are:
- Flexible enough to adapt to evolving regulations.
- Seamlessly integrated across global markets.
- Designed to enhance efficiency, allowing sales teams to focus on commercial growth rather than administrative burdens.
Additionally, investing in configurable, scalable compliance solutions - rather than rigid, expensive-to-maintain systems - will be crucial in navigating ongoing industry disruptions.
A transformational approach to compliance
Through enhanced configurability, deeper data insights, or smarter system integrations, this approach ensures compliance remains robust, even in an era of cost reduction. Unburdening expensive sales teams of clumsy, time-consuming processes will ensure their promotional effort can be utilised to full potential, as will super-powering sales reps and promotional teams with processes which enable them to make the most of opportunities and perform more competitively.
We understand that systems are increasingly expensive to maintain. Technology is not trivial, but compliance isn't a flick of a switch either. There are several steps which one must go through to ensure the engagement with a particular HCP is compliant. Starting at the recruitment process stage, we believe it’s as important for a client to understand who is unable to attend as it is to understand who is able to attend. This kind of insight is immensely helpful because if an HCP is unable to attend, from this you can learn the timings they need to attend an engagement in the future.
Cost and compliance may be colliding but, with the right strategy, organisations can navigate this intersection effectively. By embracing innovation, maintaining a human touch, and leveraging expert partnerships, pharmaceutical companies can achieve compliance excellence - without breaking the bank.